Drug intelligence / Profile preview

KV07v

Development stage: Preclinical
Lead developer: Biohaven
Modality: Small Molecules
Administration: Topical

Overview

KV07v is a preclinical-stage phytopharmaceutical candidate developed by Kensana Health. It is a cannabinoid-based therapeutic designed to modulate the endocannabinoid system (ECS). The drug is being investigated for the treatment of conditions affecting the vaginal and peri-anal regions. As a phytopharmaceutical, it is derived from plant sources, specifically targeting the biological pathways associated with the ECS to provide therapeutic relief in localized dermatological or mucosal indications.

Beyond the preview

Go deeper on KV07v.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KV07v.

Explore the full profile